, Volume 19, Issue 5, pp 551–563

Economic Evaluation of a New Acellular Vaccine for Pertussis in Canada

  • Michael Iskedjian
  • Thomas R. Einarson
  • Bernie J. O’Brien
  • J. Gaston De Serres
  • Ron Gold
  • Ian M. Gemmill
  • Natalie Milkovich
  • Andrew Rosner
Original Research Article

DOI: 10.2165/00019053-200119050-00009

Cite this article as:
Iskedjian, M., Einarson, T.R., O’Brien, B.J. et al. Pharmacoeconomics (2001) 19: 551. doi:10.2165/00019053-200119050-00009


Objective: Pertussis is a highly contagious infection affecting mainly children. Acellular pertussis vaccines were recently introduced in Canada based on evidence of improved safety and efficacy overwhole cell vaccines, the current standard of care. The following study reports the economic impact of replacing the whole cell vaccine (wP) by a new acellular vaccine (aP) in the Ontario pertussis immunisation programme.

Design: For a hypothetical cohort of 100 000 children from birth to the age of 8 years, the costs and consequences of pertussis vaccination with either aP or wP were compared. A decision analytical modelwas constructed for vaccine delivery, treatment of pertussis cases and vaccine adverse events, with analyses from the viewpoints of the Ontario Ministry of Health and society.

Main outcome measures and results: The main outcomes were expected number of pertussis cases, hospitalisations, and workdays lost by parents. Data on vaccine effectiveness, pertussis incidence, and other parameters used in the model were from published literature. Costs were discounted at 5%, and extensive sensitivity analyses were undertaken.

Over 8 years, in a cohort of 100 000 children, the introduction of aP would prevent 10 500 cases of pertussis, avoiding 504 hospital admissions and 73 500 days of work absence. For Ontario, healthcare cost savings over the same period would amount to 275 585 Canadian dollars ($Can), and societal savings to $Can9 752 864 (1997values). Results were sensitive to both incidence of pertussis and vaccine efficacy.

Conclusion: This study suggests that even though the new acellular vaccine has a higher acquisition cost than the currentwhole cell vaccine, its improved efficacy and safety result in overall cost savings.

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • Michael Iskedjian
    • 1
  • Thomas R. Einarson
    • 2
    • 3
  • Bernie J. O’Brien
    • 4
    • 5
  • J. Gaston De Serres
    • 6
  • Ron Gold
    • 7
  • Ian M. Gemmill
    • 8
  • Natalie Milkovich
    • 9
  • Andrew Rosner
    • 10
  1. 1.PharmIdeas Research & Consulting IncHamiltonCanada
  2. 2.Faculty of PharmacyUniversity of TorontoTorontoCanada
  3. 3.Department of Clinical PharmacologyHospital for Sick ChildrenTorontoCanada
  4. 4.Department of Clinical Epidemiology and BiostatisticsMcMaster UniversityHamiltonCanada
  5. 5.Centre for Evaluation of MedicinesSt Joseph’s HospitalHamiltonCanada
  6. 6.Centre de Santé Publique de QuébecQuébec CityCanada
  7. 7.Gold Medical ConsultantTorontoCanada
  8. 8.Kingston, Frontenac, Lennox and Addington Health UnitKingstonCanada
  9. 9.University of TorontoTorontoCanada
  10. 10.Innovus Research IncBurlingtonCanada

Personalised recommendations